BRIEF-Novo Nordisk Signs Up To $2.1 Bln Asset Purchase & License Deal With Omeros

Reuters

Oct 15, 2025

BRIEF-<a href="https://laohu8.com/S/NVO">Novo Nordisk</a> Signs Up To $2.1 Bln Asset Purchase & License Deal With Omeros

Oct 15 (Reuters) - Novo Nordisk A/S NOVOb.CO:

NOVO NORDISK: OMEROS ELIGIBLE TO RECEIVE $340 MILLION IN UPFRONT & NEAR-TERM MILESTONE PAYMENTS, UP TO $2.1 BILLION
NOVO NORDISK: UNDER DEAL TERMS, CO TO BE GRANTED EXCLUSIVE GLOBAL RIGHTS TO DEVELOP, COMMERCIALISE ZALTENIBART IN ALL INDICATIONS
NOVO NORDISK: OMEROS RETAINS SOME RIGHTS TO ITS PRECLINICAL MASP-3 PROGRAMMES UNRELATED TO ZALTENIBART
NOVO NORDISK: CO & OMEROS ENTER ASSET PURCHASE & LICENSE DEAL FOR OMEROS’ CLINICAL-STAGE MASP-3 INHIBITOR ZALTENIBART

Further company coverage: [NOVOb.CO]

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2575782149"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575782149\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575782149?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-15 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575782149","market":"fut","top_or_hot":-1,"title":"BRIEF-Novo Nordisk Signs Up To $2.1 Bln Asset Purchase & License Deal With Omeros","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> Signs Up To $2.1 Bln Asset Purchase &amp; License Deal With Omeros</title></head><body><p><span>Oct 15 (Reuters)</span><span> - </span>Novo Nordisk A/S <span>NOVOb.CO</span>:</p><ul><li><p>NOVO NORDISK: OMEROS ELIGIBLE TO RECEIVE $340 MILLION IN UPFRONT &amp; NEAR-TERM MILESTONE PAYMENTS, UP TO $2.1 BILLION</p></li><li><p>NOVO NORDISK: UNDER DEAL TERMS, CO TO BE GRANTED EXCLUSIVE GLOBAL RIGHTS TO DEVELOP, COMMERCIALISE ZALTENIBART IN ALL INDICATIONS</p></li><li><p>NOVO NORDISK: OMEROS RETAINS SOME RIGHTS TO ITS PRECLINICAL MASP-3 PROGRAMMES UNRELATED TO ZALTENIBART</p></li><li><p>NOVO NORDISK: CO &amp; OMEROS ENTER ASSET PURCHASE &amp; LICENSE DEAL FOR OMEROS’ CLINICAL-STAGE MASP-3 INHIBITOR ZALTENIBART</p></li></ul><p>Further company coverage: [NOVOb.CO]</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Novo Nordisk Signs Up To $2.1 Bln Asset Purchase & License Deal With Omeros</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Novo Nordisk Signs Up To $2.1 Bln Asset Purchase & License Deal With Omeros\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-15 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> Signs Up To $2.1 Bln Asset Purchase &amp; License Deal With Omeros</title></head><body><p><span>Oct 15 (Reuters)</span><span> - </span>Novo Nordisk A/S <span>NOVOb.CO</span>:</p><ul><li><p>NOVO NORDISK: OMEROS ELIGIBLE TO RECEIVE $340 MILLION IN UPFRONT &amp; NEAR-TERM MILESTONE PAYMENTS, UP TO $2.1 BILLION</p></li><li><p>NOVO NORDISK: UNDER DEAL TERMS, CO TO BE GRANTED EXCLUSIVE GLOBAL RIGHTS TO DEVELOP, COMMERCIALISE ZALTENIBART IN ALL INDICATIONS</p></li><li><p>NOVO NORDISK: OMEROS RETAINS SOME RIGHTS TO ITS PRECLINICAL MASP-3 PROGRAMMES UNRELATED TO ZALTENIBART</p></li><li><p>NOVO NORDISK: CO &amp; OMEROS ENTER ASSET PURCHASE &amp; LICENSE DEAL FOR OMEROS’ CLINICAL-STAGE MASP-3 INHIBITOR ZALTENIBART</p></li></ul><p>Further company coverage: [NOVOb.CO]</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OMER","symbol_name":"奥麦罗制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nP8N3FY047:1","article_id":"2575782149","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575782149","pubTimestamp":1760531407,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Novo Nordisk Signs Up To $2.1 Bln Asset Purchase & License Deal With OmerosOct 15  - Novo Nordisk A/S NOVOb.CO:NOVO NORDISK: OMEROS ELIGIBLE TO RECEIVE $340 MILLION IN UPFRONT & NEAR-TERM MILESTONE PAYMENTS, UP TO $2.1 BILLIONNOVO NORDISK: UNDER DEAL TERMS, CO TO BE GRANTED EXCLUSIVE GLOBAL RIGHTS TO DEVELOP, COMMERCIALISE ZALTENIBART IN ALL INDICATIONSNOVO NORDISK: OMEROS RETAINS SOME RIGHTS TO ITS PRECLINICAL MASP-3 PROGRAMMES UNRELATED TO ZALTENIBARTNOVO NORDISK: CO & OMEROS ENTER ASSET PURCHASE & LICENSE DEAL FOR OMEROS’ CLINICAL-STAGE MASP-3 INHIBITOR ZALTENIBARTFurther company coverage: [NOVOb.CO]","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OMER":"奥麦罗制药","BK4007":"制药"},"translate_title":"简报-诺和诺德与Omeros签署价值21亿美元的资产购买和许可协议","themeId":"05c55ca8ae3b47a610136310aedf4cb1","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMER":0.9},"content_text":"BRIEF-Novo Nordisk Signs Up To $2.1 Bln Asset Purchase & License Deal With OmerosOct 15 (Reuters) - Novo Nordisk A/S NOVOb.CO:NOVO NORDISK: OMEROS ELIGIBLE TO RECEIVE $340 MILLION IN UPFRONT & NEAR-TERM MILESTONE PAYMENTS, UP TO $2.1 BILLIONNOVO NORDISK: UNDER DEAL TERMS, CO TO BE GRANTED EXCLUSIVE GLOBAL RIGHTS TO DEVELOP, COMMERCIALISE ZALTENIBART IN ALL INDICATIONSNOVO NORDISK: OMEROS RETAINS SOME RIGHTS TO ITS PRECLINICAL MASP-3 PROGRAMMES UNRELATED TO ZALTENIBARTNOVO NORDISK: CO & OMEROS ENTER ASSET PURCHASE & LICENSE DEAL FOR OMEROS’ CLINICAL-STAGE MASP-3 INHIBITOR ZALTENIBARTFurther company coverage: [NOVOb.CO]","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}